SDX 102

Drug Profile

SDX 102

Alternative Names: Alanosine; L-alanosine; NSC-153353

Latest Information Update: 25 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); University of California, San Diego
  • Developer Salmedix
  • Class Cytostatic antibiotics
  • Mechanism of Action Adenylosuccinate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain cancer; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma

Most Recent Events

  • 16 Jun 2005 Salmedix has been acquired by Cephalon
  • 04 May 2005 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV)
  • 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top